Travoprost STADA 40 microgram/ml oogdruppels, oplossing

Land: Nederland

Taal: Nederlands

Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

Werkstoffen:

TRAVOPROST

Beschikbaar vanaf:

Stada Arzneimittel AG Stadastrasse 2-18 61118 BAD VILBEL (DUITSLAND)

ATC-code:

S01EE04

INN (Algemene Internationale Benaming):

TRAVOPROST

farmaceutische vorm:

Oogdruppels, oplossing

Samenstelling:

BOORZUUR (E 284) ; MACROGOLGLYCEROLHYDROXYSTEARAAT ; MANNITOL (D-) (E 421) ; NATRIUMCHLORIDE ; NATRIUMHYDROXIDE (E 524) ; POLYQUATERNIUM-1 ; PROPYLEENGLYCOL (E 1520) 7,5 mg/ml ; WATER, GEZUIVERD ; ZOUTZUUR (E 507),

Toedieningsweg:

Oculair gebruik

Therapeutisch gebied:

Travoprost

Product samenvatting:

Hulpstoffen: BOORZUUR (E 284); MACROGOLGLYCEROLHYDROXYSTEARAAT; MANNITOL (D-) (E 421); NATRIUMCHLORIDE; NATRIUMHYDROXIDE (E 524); POLYQUATERNIUM-1; PROPYLEENGLYCOL (E 1520) 7,5 mg/ml; WATER, GEZUIVERD; ZOUTZUUR (E 507);

Autorisatie datum:

2015-02-21

Bijsluiter

Travoprost STADA, NL3029
2020-08-17
1
PACKAGE LEAFLET: INFORMATION FOR THE USER
Travoprost STADA 40 microgram/ml oogdruppels, oplossing
Travoprost
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if
their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Travoprost STADA is and what it is used for
2.
What you need to know before you use Travoprost STADA
3.
How to use Travoprost STADA
4.
Possible side effects
5.
How to store Travoprost STADA
6.
Contents of the pack and other information
1.
WHAT TRAVOPROST STADA IS AND WHAT IT IS USED FOR
TRAVOPROST STADA CONTAINS TRAVOPROST
, one of a group of medicines called
PROSTAGLANDIN ANALOGUES
. It
works by reducing the pressure in the eye. It may be used on its own
or with other drops e.g. beta-blockers,
which also reduce pressure.
TRAVOPROST STADA IS USED TO REDUCE HIGH PRESSURE IN THE EYE IN ADULTS.
This pressure can lead to an
illness called glaucoma.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE TRAVOPROST STADA
DO NOT USE TRAVOPROST STADA
•
IF YOU ARE ALLERGIC
to Travoprost STADA or any of the other ingredients of this medicine
(listed in
section 6).
Ask your doctor for advice if this applies to you.
WARNINGS AND PRECAUTIONS
Talk to your doctor or, pharmacist before using Travoprost STADA:
•
Travoprost STADA MAY INCREASE
the length, thickness, colour and/or number of your
EYELASHES
.
Changes in the eyelids including unusual hair growth or in the tissues
around the eye have also been
observed.
•
Travoprost STADA
may
CHANGE THE COLOUR OF YOUR IRIS
(the coloured part of your eye). This change
may be permanent. A

Productkenmerken

Travoprost SmPC, NL3029,
2020-08-17
SUMMARY OF PRODUCT CHARACTERISTICS
Travoprost SmPC, NL3029,
2020-08-17
1.
NAME OF THE MEDICINAL PRODUCT
Travoprost STADA 40 microgram/ml oogdruppels, oplossing
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each mL of solution contains 40 micrograms of travoprost.
Excipient(s) with known effect:
Each mL of solution contains 2 mg of macrogolglycerol hydroxystearate
40.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Eye drops, solution. (Eye drops)
Clear, colourless solution.
pH 6.3 to 7.3;
osmolality 265 - 320 mOsmol/kg
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Decrease of elevated intraocular pressure in adult patients with
ocular hypertension or open-angle
glaucoma (see section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Posology _
Use in adults, including elderly population
The dose is one drop of Travoprost STADA in the conjunctival sac of
the affected eye(s) once daily.
Optimal effect is obtained if the dose is administered in the evening.
Nasolacrimal occlusion or gently closing the eyelid after
administration is recommended. This may
reduce the systemic absorption of medicinal products administered via
the ocular route and result in a
decrease in systemic adverse reactions.
If more than one topical ophthalmic medicinal product is being used,
the medicinal products must be
administered at least 5 minutes apart (see section 4.5).
If a dose is missed, treatment should be continued with the next dose
as planned. The dose should not
exceed one drop in the affected eye(s) daily.
When substituting another ophthalmic antiglaucoma medicinal product
with travoprost eye drops, the
other medicinal product should be discontinued and travoprost eye
drops should be started the
following day.
Travoprost SmPC, NL3029,
2020-08-17
Patients with hepatic and renal impairment
Travoprost has been studied in patients with mild to severe hepatic
impairment and in patients with
mild to severe renal impairment (creatinine clearance as low as 14
ml/min). No dosa